NCT05463952View on ClinicalTrials.gov

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

May 4, 2023

Study Completion Date

March 31, 2025

Conditions
Breast Neoplasms
Interventions
DRUG

vepdegestrant

ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.

Trial Locations (3)

464-8681

Aichi Cancer Center Hospital, Nagoya

277-8577

National Cancer Center Hospital East, Kashiwa

104-0045

National Cancer Center Hospital, Chuo-ku

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arvinas Estrogen Receptor, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT05463952 - A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC) | Biotech Hunter | Biotech Hunter